Charles River Laboratories International (NYSE:CRL) Cut to Neutral at The Goldman Sachs Group
The Goldman Sachs Group downgraded shares of Charles River Laboratories International (NYSE:CRL – Free Report) from a buy rating to a neutral rating in a report issued on Friday, MarketBeat Ratings reports. They currently have $170.00 price objective on the medical research company’s stock, down from their prior price objective of $190.00. Several other equities […]
The Goldman Sachs Group downgraded shares of Charles River Laboratories International (NYSE:CRL – Free Report) from a buy rating to a neutral rating in a report issued on Friday, MarketBeat Ratings reports. They currently have $170.00 price objective on the medical research company’s stock, down from their prior price objective of $190.00. Several other equities […]
